CEBPB and Familial prostate cancer: In prostate cancer (PC) cells, DDIT4 enhances CCAAT/enhancer-binding protein beta (C/EBPbeta)-mediated autophagosome-lysosome fusion and desensitizes the cells to bortezomib [6].